Bridgeway Capital Management’s TherapeuticsMD TXMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$34.3K Hold
17,000
﹤0.01% 1198
2025
Q4
$27.7K Sell
17,000
-17,000
-50% -$24.6K ﹤0.01% 1202
2025
Q3
$36K Hold
34,000
﹤0.01% 1178
2025
Q2
$39.4K Hold
34,000
﹤0.01% 1142
2025
Q1
$31.4K Hold
34,000
﹤0.01% 1141
2024
Q4
$29.2K Hold
34,000
﹤0.01% 1175
2024
Q3
$56.4K Hold
34,000
﹤0.01% 1204
2024
Q2
$54.7K Sell
34,000
-5,100
-13% -$10.3K ﹤0.01% 1207
2024
Q1
$89.5K Sell
39,100
-2,900
-7% -$6.71K ﹤0.01% 1218
2023
Q4
$94.5K Hold
42,000
﹤0.01% 1250
2023
Q3
$127K Hold
42,000
﹤0.01% 1179
2023
Q2
$173K Hold
42,000
﹤0.01% 1168
2023
Q1
$158K Hold
42,000
﹤0.01% 1148
2022
Q4
$235K Buy
42,000
+27,000
+180% +$159K 0.01% 1051
2022
Q3
$100K Buy
+15,000
New +$121K ﹤0.01% 1267
2021
Q1
Sell
-5,510
Closed -$333K 1413
2020
Q4
$333K Hold
5,510
0.01% 1089
2020
Q3
$435K Sell
5,510
-954
-15% -$76K 0.01% 950
2020
Q2
$404K Buy
6,464
+1,534
+31% +$89.3K 0.01% 929
2020
Q1
$261K Sell
4,930
-1,168
-19% -$116K 0.01% 973
2019
Q4
$738K Buy
6,098
+2,058
+51% +$296K 0.01% 817
2019
Q3
$733K Buy
+4,040
New +$569K 0.01% 817

Other funds holding TXMD

Bridgeway Capital Management's TXMD Position: Q1 2026 in Review

Bridgeway Capital Management held its TherapeuticsMD (TXMD) position steady in Q1 2026 at 17,000 shares worth $34.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1198.

Bridgeway Capital Management first reported a position in TXMD in Q3 2019 and has held it in 21 quarters since. The position peaked at $738K in Q4 2019. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Bridgeway Capital Management held 17,000 shares of TherapeuticsMD worth $34.3K as of Q1 2026.
  • Bridgeway Capital Management left its TherapeuticsMD share count unchanged in Q1 2026.
  • TherapeuticsMD made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1198 holding.
  • Bridgeway Capital Management first reported a position in TherapeuticsMD in Q3 2019 and has held it in 21 quarters since.
  • Bridgeway Capital Management's TherapeuticsMD position peaked at $738K in Q4 2019.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.